Anja K Büscher1, Bodo B Beck2, Anette Melk3, Julia Hoefele4, Birgitta Kranz5, Daniel Bamborschke2, Sabrina Baig3, Bärbel Lange-Sperandio6, Theresa Jungraithmayr7, Lutz T Weber8, Markus J Kemper9, Burkhard Tönshoff10, Peter F Hoyer1, Martin Konrad5, Stefanie Weber11. 1. Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany; 2. Institute of Human Genetics, University of Cologne, Cologne, Germany; 3. Pediatric Nephrology, Hanover Medical School, Hanover, Germany; 4. Center for Human Genetics and Laboratory Medicine Dr. Klein, Dr. Rost and Colleagues, Martinsried, Germany; 5. Pediatric Nephrology, University Children's Hospital, Munster, Germany; 6. Pediatric Nephrology, Ludwig-Maximilians-University Munich, Munich, Germany; 7. Pediatric Nephrology, University Children's Hospital Innsbruck, Innsbruck, Austria; 8. Pediatric Nephrology, University Children's Hospital Cologne, Cologne, Germany; 9. Pediatric Nephrology, University Children´s Hospital Hamburg, Hamburg, Germany; and. 10. Department of Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany. 11. Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany; stefanie.weber@uk-essen.de.
Abstract
BACKGROUND AND OBJECTIVES: Treatment of congenital nephrotic syndrome (CNS) and steroid-resistant nephrotic syndrome (SRNS) is demanding, and renal prognosis is poor. Numerous causative gene mutations have been identified in SRNS that affect the renal podocyte. In the era of high-throughput sequencing techniques, patients with nongenetic SRNS frequently escape the scientific interest. We here present the long-term data of the German CNS/SRNS Follow-Up Study, focusing on the response to cyclosporin A (CsA) in patients with nongenetic versus genetic disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional and longitudinal clinical data were collected from 231 patients with CNS/SRNS treated at eight university pediatric nephrology units with a median observation time of 113 months (interquartile range, 50-178). Genotyping was performed systematically in all patients. RESULTS: The overall mutation detection rate was high at 57% (97% in CNS and 41% in SRNS); 85% of all mutations were identified by the analysis of three single genes only (NPHS1, NPHS2, and WT1), accounting for 92% of all mutations in patients with CNS and 79% of all mutations in patients with SRNS. Remission of the disease in nongenetic SRNS was observed in 78% of patients after a median treatment period of 2.5 months; 82% of nongenetic patients responded within 6 months of therapy, and 98% of patients with nongenetic SRNS and CsA-induced complete remission (normalbuminemia and no proteinuria) maintained a normal renal function. Genetic SRNS, on the contrary, is associated with a high rate of ESRD in 66% of patients. Only 3% of patients with genetic SRNS experienced a complete remission and 16% of patients with genetic SRNS experienced a partial remission after CsA therapy. CONCLUSIONS: The efficacy of CsA is high in nonhereditary SRNS, with an excellent prognosis of renal function in the large majority of patients. CsA should be given for a minimum period of 6 months in these patients with nongenetic SRNS. In genetic SRNS, response to CsA was low and restricted to exceptional patients.
BACKGROUND AND OBJECTIVES: Treatment of congenital nephrotic syndrome (CNS) and steroid-resistant nephrotic syndrome (SRNS) is demanding, and renal prognosis is poor. Numerous causative gene mutations have been identified in SRNS that affect the renal podocyte. In the era of high-throughput sequencing techniques, patients with nongenetic SRNS frequently escape the scientific interest. We here present the long-term data of the German CNS/SRNS Follow-Up Study, focusing on the response to cyclosporin A (CsA) in patients with nongenetic versus genetic disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional and longitudinal clinical data were collected from 231 patients with CNS/SRNS treated at eight university pediatric nephrology units with a median observation time of 113 months (interquartile range, 50-178). Genotyping was performed systematically in all patients. RESULTS: The overall mutation detection rate was high at 57% (97% in CNS and 41% in SRNS); 85% of all mutations were identified by the analysis of three single genes only (NPHS1, NPHS2, and WT1), accounting for 92% of all mutations in patients with CNS and 79% of all mutations in patients with SRNS. Remission of the disease in nongenetic SRNS was observed in 78% of patients after a median treatment period of 2.5 months; 82% of nongenetic patients responded within 6 months of therapy, and 98% of patients with nongenetic SRNS and CsA-induced complete remission (normalbuminemia and no proteinuria) maintained a normal renal function. Genetic SRNS, on the contrary, is associated with a high rate of ESRD in 66% of patients. Only 3% of patients with genetic SRNS experienced a complete remission and 16% of patients with genetic SRNS experienced a partial remission after CsA therapy. CONCLUSIONS: The efficacy of CsA is high in nonhereditary SRNS, with an excellent prognosis of renal function in the large majority of patients. CsA should be given for a minimum period of 6 months in these patients with nongenetic SRNS. In genetic SRNS, response to CsA was low and restricted to exceptional patients.
Authors: Anja K Büscher; Martin Konrad; Mato Nagel; Oliver Witzke; Andreas Kribben; Peter F Hoyer; Stefanie Weber Journal: Clin Nephrol Date: 2012-07 Impact factor: 0.975
Authors: Anja K Büscher; Birgitta Kranz; Rainer Büscher; Friedhelm Hildebrandt; Bernd Dworniczak; Petra Pennekamp; Eberhard Kuwertz-Bröking; Anne-Margret Wingen; Ulrike John; Markus Kemper; Leo Monnens; Peter F Hoyer; Stefanie Weber; Martin Konrad Journal: Clin J Am Soc Nephrol Date: 2010-08-26 Impact factor: 8.237
Authors: An S De Vriese; Sanjeev Sethi; Karl A Nath; Richard J Glassock; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2018-01-10 Impact factor: 10.121
Authors: Agnes Trautmann; Sven Schnaidt; Beata S Lipska-Ziętkiewicz; Monica Bodria; Fatih Ozaltin; Francesco Emma; Ali Anarat; Anette Melk; Marta Azocar; Jun Oh; Bassam Saeed; Alaleh Gheisari; Salim Caliskan; Jutta Gellermann; Lina Maria Serna Higuita; Augustina Jankauskiene; Dorota Drozdz; Sevgi Mir; Ayse Balat; Maria Szczepanska; Dusan Paripovic; Alexandra Zurowska; Radovan Bogdanovic; Alev Yilmaz; Bruno Ranchin; Esra Baskin; Ozlem Erdogan; Giuseppe Remuzzi; Agnieszka Firszt-Adamczyk; Elzbieta Kuzma-Mroczkowska; Mieczyslaw Litwin; Luisa Murer; Marcin Tkaczyk; Helena Jardim; Anna Wasilewska; Nikoleta Printza; Kibriya Fidan; Eva Simkova; Halina Borzecka; Hagen Staude; Katharina Hees; Franz Schaefer Journal: J Am Soc Nephrol Date: 2017-05-31 Impact factor: 10.121